China
Huadong to Buy Exclusive Rights for First-in-Class Skin Disease Drug in China
Huadong Medicine, one of China's most diversified makers of dermatosis medicines, will purchase exclusive rights for a first-in-class skin disease treatment developed by UK firm MC2 Therapeutics in China.
Neurophth Secures Australian Approval for Ophthalmic Gene Therapy
Neurophth Therapeutics (hereinafter referred to as "Neurophth"), a leader in in-vivo gene therapy for ophthalmic diseases in China, announced the Australian Therapeutic Goods Administration (TGA) has registered and approved its candidate drug, NFS-05, for clinical trials targeting Autosomal Dominant Optic Atrophy (ADOA).
AnHeart Therapeutics Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib for IDH1-Mutant Glioma
AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the first patient has been dosed in a Phase 2 clinical trial, G203, evaluating safusidenibin patients with Grades 2 or 3 recurrent or progressive mutant isocitrate dehydrogenase 1 (mIDH1) glioma, one of the most common types of adult primary brain cancer.
SIBIONICS Launches the Breakthrough SIBIO KS1 CKM for Ketone Level Monitoring
SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels
ATLATL Beijing International Innovation Center Becomes Fully Operational
Phase II of the ATLATL Beijing International Innovation Center (referred to as "Beijing ATLATL"), located in the Zhongguancun Life Science Park, has officially commenced operations, marking the comprehensive launch of Beijing ATLATL.
Aesthetic Medical International Reports First Half of 2023 Unaudited Financial Results
Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, announced its unaudited financial results for the six months ended June 30, 2023.
Adagene to Present at Investor and Scientific Conferences in September
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company’s participation in several upcoming investor and scientific conferences.
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
Gracell announced that it will present updated, longer-term results from the ongoing investigator-initiated Phase 1 trial in China evaluating FasTCAR-enabled GC012F in transplant-eligible, high-risk patients with newly diagnosed multiple myeloma (NDMM). The findings will be presented in a poster presentation at the 20th International Myeloma Society (IMS) Annual Meeting, taking place September 27-30, 2023, in Athens, Greece and virtually.
CANbridge to Participate in Two Investor Conferences in September
CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today announced its participation in two upcoming investor conferences.
Ascletis to Participate in the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference. John Gargiulo, Chief Business Officer of Ascletis, will join the fireside chat at 2:15 pm EST on Wednesday, September 13, 2023 (i.e. 2:15 am Beijing time on Thursday, September 14, 2023).
